Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Weingarten Realty Reports Strong Same Property Net Operating Income

Published

on

Reading Time: 13 minutes

HOUSTON–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24WRI&src=ctag” target=”_blank”gt;$WRIlt;/agt; lt;a href=”https://twitter.com/hashtag/NAREITFFO?src=hash” target=”_blank”gt;#NAREITFFOlt;/agt;–Weingarten Realty (NYSE: WRI) announced today the results of its
operations for the quarter ended March 31, 2019. The supplemental
financial package with additional information can be found on the
Company’s website under the Investor Relations tab.

First Quarter Operating and Financial Highlights

  • Net income attributable to common shareholders (“Net Income”) for the
    quarter was $0.39 per diluted share (hereinafter “per share”) compared
    to $1.13 per share in the same quarter of 2018;
  • Core Funds From Operations Attributable to Common Shareholders (“Core
    FFO”) for the quarter was $0.52 per share compared to $0.57 per share
    a year ago;
  • Same Property Net Operating Income (“SPNOI”) including redevelopments
    increased 3.2% over the same quarter of the prior year;
  • Investments in acquisitions of $20.3 million; and
  • Dispositions for the quarter totaled $67 million.

Financial Results

The Company reported Net Income of $49.7 million or $0.39 per share for
the first quarter of 2019, as compared to $146.8 million or $1.13 per
share for the same period in 2018. This decrease was due primarily to
lower gains on sales of properties due to reduced disposition activity
during 2019.

Effective this quarter, the Company adopted the new standard issued by
the Financial Accounting Standards Board, ASU 2016-02, “Leases.” Among
the changes required under this new ASU are the following:

  • Indirect, internally-generated leasing and legal costs are no longer
    capitalized which resulted in an increase in general and
    administrative expenses of approximately $2.3 million for the quarter;
  • Real estate taxes paid directly by tenants are no longer included in
    revenues and expenses in the Company’s consolidated financial
    statements. Real estate taxes paid directly by tenants totaled $1.2
    million during the first quarter of 2018;
  • Ground leases where the Company is the lessee were recorded on the
    balance sheet and were amortized accordingly to rent expense; and,
  • New guidelines for assessing the collectability of accounts receivable
    and the related presentation were implemented.

This standard was adopted on a modified retrospective approach;
therefore, prior year amounts were not restated. Further details of
these issues are included on page 44 of our Supplemental.

Funds From Operations attributable to common shareholders in accordance
with the newly revised National Association of Real Estate Investment
Trusts definition (“NAREIT FFO”) was $67.3 million or $0.52 per share
for the first quarter of 2019 compared to $78.3 million or $0.60 per
share for 2018.

Core FFO for the quarter ended March 31, 2019 was the same as NAREIT FFO
at $67.3 million or $0.52 per share compared to $74.7 million or $0.57
per share for the same quarter of last year. Key factors that effected
this change of $0.05 per share from this year to last year are:

  • Disposition activity of $0.03 per share;
  • Increase of $0.02 per share for indirect leasing and legal costs
    expensed in accordance with the new leasing standard;
  • Non-cash expense increase of $0.02 per share of compensation expense
    due to lower valuations of our restricted shares for incentive
    compensation purposes offset by other reductions in overhead; and,
  • Increased SPNOI and other factors.

Effective this quarter, the Company adopted the updated definition of
NAREIT FFO and will exclude gains or losses on the sale of land parcels
and securities which were previously not adjusted in NAREIT FFO. Prior
period NAREIT FFO amounts have not been restated.

Reconciliations of Net Income to NAREIT FFO and Core FFO are included
herein.

Operating Results

For the period ending March 31, 2019, the Company’s operating highlights
were as follows:

   

Q1 2019

Occupancy (Signed Basis):    
Occupancy – Total   94.3%
Occupancy – Small Shop Spaces   90.3%
Occupancy – Same Property Portfolio   94.5%
     
Same Property Net Operating Income, with redevelopments   3.2%
     
Rental Rate Growth – Total:   3.7%
New Leases   11.5%
Renewals   2.0%
     
Leasing Transactions:    
Number of New Leases   65
New Leases – Annualized Revenue (in millions)   $4.6
Number of Renewals   145
Renewals – Annualized Revenue (in millions)   $13.4
 

A reconciliation of Net Income to SPNOI is included herein.

“Operationally, we had a solid quarter with strong Same Store results of
3.2%. However, rent growth for the quarter was below the recent norms.
Our new leases produced strong increases of 11.5%; however, our renewals
averaged only 2%. While shop renewals were a healthy 7%, a few box
renewals where the tenant had significant negotiating leverage led to a
decrease of 3% for boxes. Looking ahead to the rest of 2019, we expect
to produce rent growth in the mid-to-high single digits for the rest of
2019,” said Johnny Hendrix, Executive Vice President and Chief Operating
Officer.

Portfolio Activity

During the quarter, the Company purchased Madison Village in Central
Phoenix, Arizona at Seventh and Glendale for $20.3 million. The center
is anchored by a Safeway that produces extremely strong sales and is
located in a densely populated area of Phoenix with 140,000 people
within a three-mile radius. With 40,000 square feet of shop space,
focused leasing efforts to improve the tenancy should produce strong
growth over the next couple of years.

The Company closed $67 million of dispositions with the sale of three
shopping centers including Reynolds Crossing and Brookwood Marketplace,
both in suburban Atlanta, Georgia and Waterford Village in Leland, North
Carolina. The Company also sold one land parcel.

In addition, the Company invested $44 million in new developments and
redevelopments during the first quarter. The majority of the investment
is in its two projects in the Washington D.C. area and its 30-story
residential tower at its River Oaks Shopping Center in Houston.

“We are pleased to begin 2019 with the acquisition of a solid grocery
anchored center with outstanding sales and great upside. Our two
mixed-use developments in D.C. area are progressing nicely and will be
successful, valuable real estate projects and our significantly
transformed existing portfolio produced outstanding same property NOI of
3.2%. All of these factors should contribute to solid gains for our
shareholders,” said Drew Alexander, Chairman, President and Chief
Executive Officer.

Balance Sheet

The Company continues to maintain one of the strongest balance sheets in
its sector and proceeds from the Company’s recent dispositions were used
to further strengthen its financial position. Net Debt to Core EBITDAre
was a strong 5.3 times and Debt to Total Market Capitalization was 31.9%
at quarter end.

“Both Moody’s and S&P completed full credit analyses and confirmed our
ratings of Baa1/BBB during the first quarter. With the strongest credit
metrics we have had in many years, we are poised to take advantage of
whatever opportunities may arise. Low leverage provides the flexibility
to react quickly as market conditions change,” said Steve Richter,
Executive Vice President and Chief Financial Officer.

2019 Guidance

As to earnings guidance, the Company affirms NAREIT FFO and Core FFO per
share of a range from $2.09 to $2.17. All of the details of our guidance
are included on page 10 of our Supplemental.

Dividends

The Board of Trust Managers declared a quarterly cash dividend of $0.395
per common share payable on June 14, 2019 to shareholders of record on
June 7, 2019.

Conference Call Information

The Company also announced that it will host a live webcast of its
quarterly conference call on April 30, 2019 at 10:00 a.m. Central Time.
The live webcast can be accessed via the Company’s website at www.weingarten.com.
Alternatively, if you are not able to access the call on the web, you
can listen live by phone by calling (888) 771-4371 (conference ID #
47857841). A replay will be available through the Company’s website
starting approximately two hours following the live call.

About Weingarten Realty Investors

Weingarten Realty Investors (NYSE: WRI) is a shopping center owner,
manager and developer. At March 31, 2019, the Company owned or operated
under long-term leases, either directly or through its interest in real
estate joint ventures or partnerships, a total of 177 properties which
are located in 17 states spanning the country from coast to coast. These
properties represent approximately 34.6 million square feet of which our
interests in these properties aggregated approximately 22.6 million
square feet of leasable area. To learn more about the Company’s
operations and growth strategies, please visit www.weingarten.com.

Forward-Looking Statements

Statements included herein that state the Company’s or Management’s
intentions, hopes, beliefs, expectations or predictions of the future
are “forward-looking” statements within the meaning of the Private
Securities Litigation Reform Act of 1995 which by their nature, involve
known and unknown risks and uncertainties. The Company’s actual results,
performance or achievements could differ materially from those expressed
or implied by such statements. Reference is made to the Company’s
regulatory filings with the Securities and Exchange Commission for
information or factors that may impact the Company’s performance.

Projections involve numerous assumptions such as rental income
(including assumptions on percentage rent), interest rates, tenant
defaults, occupancy rates, volume and pricing of properties held for
disposition, volume and pricing of acquisitions, expenses (including
salaries and employee costs), insurance costs and numerous other
factors. Not all of these factors are determinable at this time and
actual results may vary from the projected results, and may be above or
below the ranges indicated. The above ranges represent management’s
estimate of results based upon these assumptions as of the date of this
press release. Accordingly, there is no assurance that our projections
will be realized.

Weingarten Realty Investors
(in thousands, except per share amounts)
Financial Statements
   
Three Months Ended
March 31,
2019 2018 (1)
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)
Revenues:
Rentals, net $ 119,826 $ 129,148
Other 3,312   3,304  
Total Revenues 123,138   132,452  
Operating Expenses:
Depreciation and amortization 33,972 38,095
Operating 24,248 23,270
Real estate taxes, net 16,131 17,639
Impairment loss 74
General and administrative 9,581   5,595  
Total Operating Expenses 84,006   84,599  
Other Income (Expense):
Interest expense, net (15,289 ) (14,672 )
Interest and other income (expense) 4,384 1,533
Gain on sale of property 17,787   109,045  
Total Other Income 6,882   95,906  
Income Before Income Taxes and Equity in Earnings of Real Estate
Joint Ventures and Partnerships
46,014 143,759
Provision for Income Taxes (177 ) (783 )
Equity in Earnings of Real Estate Joint Ventures and Partnerships,
net
5,417   5,993  
Net Income 51,254 148,969

Less: Net Income Attributable to Noncontrolling Interests

(1,588 ) (2,145 )
Net Income Attributable to Common Shareholders — Basic $ 49,666   $ 146,824  
Net Income Attributable to Common Shareholders — Diluted $ 49,666   $ 147,352  
Earnings Per Common Share — Basic $ .39   $ 1.15  
Earnings Per Common Share — Diluted $ .39   $ 1.13  

______________

(1) Reclassification of prior year’s amounts were made to conform to
current year presentation.
 
Weingarten Realty Investors
(in thousands)
Financial Statements
   
March 31,
2019
December 31,
2018
(Unaudited) (Audited)
CONDENSED CONSOLIDATED BALANCE SHEETS
ASSETS
Property $ 4,104,795 $ 4,105,068
Accumulated Depreciation (1,118,217 ) (1,108,188 )
Investment in Real Estate Joint Ventures and Partnerships, net 364,165 353,828
Unamortized Lease Costs, net 139,533 142,014
Accrued Rent, Accrued Contract Receivables and Accounts Receivable,
net
76,900 97,924
Cash and Cash Equivalents 60,570 65,865
Restricted Deposits and Mortgage Escrows 11,134 10,272
Other, net 198,783   160,178  
Total Assets $ 3,837,663   $ 3,826,961  
 
LIABILITIES AND EQUITY
Debt, net $ 1,788,551 $ 1,794,684
Accounts Payable and Accrued Expenses 79,459 113,175
Other, net 209,219   168,403  
Total Liabilities 2,077,229   2,076,262  
 
Commitments and Contingencies
 
EQUITY
Common Shares of Beneficial Interest 3,903 3,893
Additional Paid-In Capital 1,777,089 1,766,993
Net Income Less Than Accumulated Dividends (187,581 ) (186,431 )
Accumulated Other Comprehensive Loss (10,480 ) (10,549 )
Shareholders’ Equity 1,582,931 1,573,906
Noncontrolling Interests 177,503   176,793  
Total Liabilities and Equity $ 3,837,663   $ 3,826,961  
 

Non-GAAP Financial Measures

Certain aspects of our key performance indicators are considered
non-GAAP financial measures. Management uses these measures along with
our Generally Accepted Accounting Principles (“GAAP”) financial
statements in order to evaluate our operating results. Management
believes these additional measures provide users of our financial
information additional comparable indicators of our industry, as well
as, our performance.

Funds from Operations Attributable to Common
Shareholders

Effective January 1, 2019, the National Association of Real Estate
Investment Trusts (“NAREIT”) defines NAREIT FFO as net income (loss)
attributable to common shareholders computed in accordance with GAAP,
excluding gains or losses from sales of certain real estate assets
(including: depreciable real estate with land, land, development
property and securities), change in control, and interests in real
estate equity investments and their applicable taxes, plus depreciation
and amortization related to real estate and impairment of certain real
estate assets and in substance real estate equity investments, including
our share of unconsolidated real estate joint ventures and partnerships.
The Company calculates NAREIT FFO in a manner consistent with the NAREIT
definition.

Management believes NAREIT FFO is a widely recognized measure of REIT
operating performance which provides our shareholders with a relevant
basis for comparison among other REITs. Management uses NAREIT FFO as a
supplemental internal measure to conduct and evaluate our business
because there are certain limitations associated with using GAAP net
income by itself as the primary measure of our operating performance.
Historical cost accounting for real estate assets in accordance with
GAAP implicitly assumes that the value of real estate assets diminishes
predictably over time. Since real estate values instead have
historically risen or fallen with market conditions, management believes
that the presentation of operating results for real estate companies
that uses historical cost accounting is insufficient by itself. There
can be no assurance that NAREIT FFO presented by the Company is
comparable to similarly titled measures of other REITs.

The Company also presents Core FFO as an additional supplemental measure
as it is more reflective of the core operating performance of our
portfolio of properties. Core FFO is defined as NAREIT FFO excluding
charges and gains related to non-cash, non-operating assets and other
transactions or events that hinder the comparability of operating
results. Specific examples of items excluded from Core FFO include, but
are not limited to, gains or losses associated with the extinguishment
of debt or other liabilities and transactional costs associated with
development activities. NAREIT FFO and Core FFO should not be considered
as alternatives to net income or other measurements under GAAP as
indicators of operating performance or to cash flows from operating,
investing or financing activities as measures of liquidity. NAREIT FFO
and Core FFO do not reflect working capital changes, cash expenditures
for capital improvements or principal payments on indebtedness.

NAREIT FFO and Core FFO is calculated as follows (in thousands):

 
  Three Months Ended
March 31,
2019   2018
(Unaudited)
Net income attributable to common shareholders $ 49,666   $ 146,824
Depreciation and amortization of real estate 33,743 37,765
Depreciation and amortization of real estate of unconsolidated real
estate joint ventures and partnerships
2,952 3,184
Impairment of properties and real estate equity investments 74
(Gain) on sale of property, investment securities and interests in
real estate equity investments
(18,949 ) (109,038 )
(Gain) on dispositions of unconsolidated real estate joint ventures
and partnerships
(274 ) (2,363 )
Provision for income taxes (1) 161
Noncontrolling interests and other (2) (489 ) 1,210  
NAREIT FFO – basic (3) 66,723 77,743
Income attributable to operating partnership units 528   528  
NAREIT FFO – diluted (3) 67,251   78,271  
Adjustments to Core FFO:
(Gain) on extinguishment of debt including related swap activity   (3,557 )
Core FFO – diluted $ 67,251   $ 74,714  
 
FFO weighted average shares outstanding – basic 127,756 127,926
Effect of dilutive securities:
Share options and awards 834 781
Operating partnership units 1,432   1,432  
FFO weighted average shares outstanding – diluted 130,022   130,139  
 
NAREIT FFO per common share – basic $ .52   $ .61  
 
NAREIT FFO per common share – diluted $ .52   $ .60  
 
Core FFO per common share – diluted $ .52   $ .57  
 
(1)   The applicable taxes related to gains and impairments of properties.
(2) Related to gains, impairments and depreciation on operating
properties and unconsolidated real estate joint ventures, where
applicable.
(3) 2019 Nareit FFO is presented in accordance with 2018 Restatement of
“Nareit’s Funds from Operations White Paper.”
 

Same Property Net Operating Income

Management considers SPNOI an important additional financial measure
because it reflects only those income and expense items that are
incurred at the property level and when compared across periods,
reflects the impact on operations from trends in occupancy rates, rental
rates and operating costs. The Company calculates this most useful
measurement by determining our proportional share of SPNOI from all
owned properties, including the Company’s share of SPNOI from
unconsolidated joint ventures and partnerships, which cannot be readily
determined under GAAP measurements and presentation. Although SPNOI (see
page 1 of the supplemental disclosure regarding this presentation and
limitations thereof) is a widely used measure among REITs, there can be
no assurance that SPNOI presented by the Company is comparable to
similarly titled measures of other REITs. Additionally, the Company does
not control these unconsolidated joint ventures and partnerships, and
the assets, liabilities, revenues or expenses of these joint ventures
and partnerships, as presented, do not represent its legal claim to such
items.

Properties are included in the SPNOI calculation if they are owned and
operated for the entirety of the most recent two fiscal year periods,
except for properties for which significant redevelopment or expansion
occurred during either of the periods presented, and properties that
have been sold. While there is judgment surrounding changes in
designations, management moves new development and redevelopment
properties once they have stabilized, which is typically upon attainment
of 90% occupancy. A rollforward of the properties included in the
Company’s same property designation is as follows:

  Three Months Ended
March 31, 2019
Beginning of the period 171
Properties added:
New Developments 1
Properties removed:
Dispositions (4 )
End of the period 168  
 

We calculate SPNOI using net income attributable to common shareholders
excluding net income attributable to noncontrolling interests, other
income (expense), income taxes and equity in earnings of real estate
joint ventures and partnerships. Additionally to reconcile to SPNOI, we
exclude the effects of property management fees, certain non-cash
revenues and expenses such as straight-line rental revenue and the
related reversal of such amounts upon early lease termination,
depreciation and amortization, impairment losses, general and
administrative expenses and other items such as lease cancellation
income, environmental abatement costs, demolition expenses and lease
termination fees. Consistent with the capital treatment of such costs
under GAAP, tenant improvements, leasing commissions and other direct
leasing costs are excluded from SPNOI. A reconciliation of net income
attributable to common shareholders to SPNOI is as follows (in
thousands):

  Three Months Ended
March 31,
2019   2018
(Unaudited)
Net income attributable to common shareholders $ 49,666 $ 146,824
Add:
Net income attributable to noncontrolling interests 1,588 2,145
Provision for income taxes 177 783
Interest expense, net 15,289 14,672
Property management fees 873 867
Depreciation and amortization 33,972 38,095
Impairment loss 74
General and administrative 9,581 5,595
Other (1) 444 89
Less:
Gain on sale of property (17,787 ) (109,045 )
Equity in earnings of real estate joint ventures and partnership
interests, net
(5,417 ) (5,993 )
Interest and other income/expense (4,384 ) (1,533 )
Revenue adjustments (2) (3,219 ) (3,932 )
Adjusted income 80,857 88,567
Less: Adjusted income related to consolidated entities not defined
as same property and noncontrolling interests
44 (10,511 )
Add: Pro rata share of unconsolidated entities defined as same
property
8,308   8,374  
Same Property Net Operating Income 89,209 86,430
Less: Redevelopment Net Operating Income (7,793 ) (7,084 )
Same Property Net Operating Income excluding Redevelopments $ 81,416     $ 79,346  

___________________

(1)   Other includes items such as environmental abatement costs,
demolition expenses and lease termination fees.
(2) Revenue adjustments consist primarily of straight-line rentals,
lease cancellation income and fee income primarily from real estate
joint ventures and partnerships.
 

Earnings Before Interest, Taxes, Depreciation
and Amortization for Real Estate

NAREIT defines EBITDAre as net income computed in accordance with GAAP,
plus interest expense, income tax expense (benefit), depreciation and
amortization and impairment of depreciable real estate and in substance
real estate equity investments; plus or minus gains or losses from sales
of certain real estate assets and interests in real estate equity
investments; and adjustments to reflect our share of unconsolidated real
estate joint ventures and partnerships for these items. The Company
calculates EBITDAre in a manner consistent with the NAREIT definition.

As mentioned above, NAREIT FFO is a widely recognized measure of REIT
operating performance which provides our shareholders with a relevant
basis for comparing earnings performance among other REITs based upon
the unique capital structure of each REIT. However as a basis of
comparability that is independent of a company’s capital structure,
management believes that since EBITDA is a widely known and understood
measure of performance, EBITDAre will represent an additional
supplemental non-GAAP performance measure that will provide investors
with a relevant basis for comparing REITs. There can be no assurance
that EBITDAre as presented by the Company is comparable to similarly
titled measures of other REITs.

The Company also presents Core EBITDAre as an additional supplemental
measure as it is more reflective of the core operating performance of
our portfolio of properties. Core EBITDAre is defined as NAREIT EBITDAre
excluding charges and gains related to non-cash and non-operating
transactions and other events that hinder the comparability of operating
results.

Contacts

Michelle Wiggs, Phone: (713) 866-6050

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care

Published

on

Continue Reading

Innocan

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Published

on

innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use

HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.

With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].

Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.

Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.

Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:

“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market

[2] https://www.cdc.gov/opioids/data/index.html

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html

Continue Reading

Curaleaf

Curaleaf Completes Acquisition of Northern Green Canada

Published

on

curaleaf-completes-acquisition-of-northern-green-canada

Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom

NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.

Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.

“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”

The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.

Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.

About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania